Helixor M

Helixor M is a prescription‑only liquid extract containing Viscum album subsp. album var. Malus domestica, prepared at a 1:20 ratio in water and supplied for subcutaneous injection. It is marketed in the European Union and classified as a herbal botanical product. The formulation is intended for use under medical supervision, typically in clinical settings where investigational or adjunctive therapy is considered.

Helixor M is used in clinical practice primarily as an adjunctive therapy in supportive care, particularly in oncology settings, although it does not have an approved therapeutic indication in most jurisdictions.

- Investigational use as complementary therapy in cancer care. - Applied in studies evaluating quality‑of‑life outcomes. - Utilized in protocols exploring immunomodulatory effects of mistletoe extracts. - Administered under physician supervision as part of individualized treatment plans.

Adverse reactions reported with subcutaneous Viscum album extracts vary in frequency and severity.

Common: - Local redness or swelling at injection site. - Mild fever or flu‑like symptoms. - Transient headache. - Nausea or mild gastrointestinal discomfort.

Serious: - Allergic reactions including urticaria or angioedema. - Severe hypotension or anaphylactic shock. - Significant liver enzyme elevation. - Persistent high fever.

Healthcare providers should consider several precautionary measures before prescribing Helixor M.

- Assess patient for known hypersensitivity to mistletoe or related plants. - Review medical history for autoimmune disorders. - Monitor vital signs during initial administrations. - Evaluate liver function tests periodically. - Use caution in patients receiving immunosuppressive therapy. - Avoid use during pregnancy or lactation unless benefits outweigh risks.

Helixor M may interact with other agents, requiring attention to avoid adverse outcomes.

Avoid: - Concurrent use with other immunostimulatory botanicals without medical oversight. - Combination with anticoagulants that increase bleeding risk.

Use with caution: - Concomitant chemotherapy agents (potential additive immunomodulation). - Vaccines (possible alteration of immune response). - Drugs metabolized by hepatic enzymes (monitor liver function).